NCT05331911 Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
| NCT ID | NCT05331911 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital |
| Condition | Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-04-26 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 500 participants in total. It began in 2022-04-26 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary Hepatocellular carcinoma. The study will enroll approximately 500 volunteers to compare the progression-free or overall survival in patients undergoing elective partial hepatectomy for primary liver tumors between propofol and sevoflurane for the maintenance of anesthesia.
Eligibility Criteria
Inclusion Criteria: 1. Twenty to eighty-year-old. 2. ASA class I-III. 3. Patients undergoing partial hepatectomy for hepatocellular carcinoma under general anesthesia. Exclusion Criteria: 1. Severe mental disorder 2. Pregnant or lactating women 3. Morbidly obese 4. Allergy to any of the drugs used in this study 5. Recurrent tumor or repeat surgery 6. Biopsy cases 7. Incomplete data collection before the surgery 8. Palliative treatment after surgery 9. simultaneous treatment of other malignancies 10. Combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine 11. Diagnosed as benign liver tumor 12. Emergency surgery
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05331911 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 80 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05331911 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT05331911 currently recruiting?
Yes, NCT05331911 is actively recruiting participants. Contact the research team at kindtaco@gmail.com for enrollment information.
Where is the NCT05331911 trial being conducted?
This trial is being conducted at Kaohsiung City, Taiwan.
Who is sponsoring the NCT05331911 clinical trial?
NCT05331911 is sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.